Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): Study protocol for a randomised controlled trial

Trials

Volumn 13, Issue , 2012, Pages

  Thwaites, Guy ^a   Auckland, Cressida ^b   Barlow, Gavin ^c   Cunningham, Richard ^d   Davies, Gerry ^e,f   Edgeworth, Jonathan ^a   Greig, Julia ^g   Hopkins, Susan ^h   Jeyaratnam, Dakshika ⁱ   Jenkins, Neil ^j   Llewelyn, Martin ^k   Meisner, Sarah ^l   Nsutebu, Emmanuel ^f   Planche, Tim ^m   Read, Robert C ⁿ   Scarborough, Matthew ^o   Soares, Marta ^p   Tilley, Robert ^d   Török, M Estée ^q   Williams, John ^r   Wilson, Peter ^s   Wyllie, Sarah ^t   Walker, A Sarah ^u,v   more..

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^c HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^d PLYMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^g SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

ⁱ KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^k Worthing Hospital   (United Kingdom)

^l ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST   (United Kingdom)

^m ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁿ SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^o OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^p UNIVERSITY OF YORK   (United Kingdom)

^q CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^r SOUTH TEES HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^s UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^t PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^u MRC CLINICAL TRIALS UNIT   (United Kingdom)

^v JOHN RADCLIFFE HOSPITAL   (United Kingdom)

more..

Author keywords

Bacteraemia; Mortality; Rifampicin; Staphylococcus aureus

Indexed keywords

DAPTOMYCIN; FLUCLOXACILLIN; LINEZOLID; PLACEBO; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HUMAN; MORTALITY; MULTICENTER STUDY (TOPIC); PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STAPHYLOCOCCAL BACTEREMIA;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CLINICAL PROTOCOLS; HUMANS; RIFAMPIN; SAMPLE SIZE; STAPHYLOCOCCAL INFECTIONS;

EID: 84871173867     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-13-241     Document Type: Article

References (37)

1. Health Protection Agency Voluntary reporting of Staphylococcus aureus bacteraemia in England, Wales, and Northern Ireland January - December 2008 http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1258560519595, Health Protection Agency.
2. Wyllie DH, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 2006, 333:281. 10.1136/bmj.38834.421713.2F, 1526943, 16798756.
3. Elliott TS, Foweraker J, Gould FK, Perry JD, Sandoe JA. Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2004, 54:971-981. 10.1093/jac/dkh474, 15546974.
4. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006, 57:589-608. 10.1093/jac/dkl017, 16507559.
5. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 49:1-45. 10.1086/599376, 19489710.
6. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011, 52:285-292. 10.1093/cid/cir034, 21217178.
7. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Torok ME, Walker S, Wertheim HF, Wilson P, Llewelyn MJ. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis 2011, 11:208-222. 10.1016/S1473-3099(10)70285-1, 21371655.
8. Naber CK, Baddour LM, Giamarellos-Bourboulis EJ, Gould IM, Herrmann M, Hoen B, Karchmer AW, Kobayashi Y, Kozlov RS, Lew D, et al. Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin Infect Dis 2009, 48(Suppl 4):S260-S270.
9. Cadena J, Restrepo MI. Methicillin-Resistant Staphylococcus aureus Guidelines: A Myriad of Open Questions. Clin Infect Dis 2011, 53:97-98. 10.1093/cid/cir278, 3110283, 21653313.
10. Fowler VG, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, Cheng AC, Dudley T, Oddone EZ. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003, 163:2066-2072. 10.1001/archinte.163.17.2066, 14504120.
11. Khatib R, Johnson LB, Fakih MG, Riederer K, Khosrovaneh A, Shamse Tabriz M, Sharma M, Saeed S. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006, 38:7-14. 10.1080/00365540500372846, 16338832.
12. Khatib R, Johnson LB, Sharma M, Fakih MG, Ganga R, Riederer K. Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand J Infect Dis 2009, 41:4-9. 10.1080/00365540802441711, 18821135.
13. Thwaites GE, Gant V. Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus?. Nat Rev Microbiol 2011, 9:215-222. 10.1038/nrmicro2508, 21297670.
14. Buniva G, Pagani V, Carozzi A. Bioavailability of rifampicin capsules. Int J Clin Pharmacol Ther Toxicol 1983, 21:404-409.
15. Mandell GL. Interaction of intraleukocytic bacteria and antibiotics. J Clin Invest 1973, 52:1673-1679. 10.1172/JCI107348, 302442, 4718959.
16. Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Am 2003, 17:615-634. 10.1016/S0891-5520(03)00066-7, 14711080.
17. Saginur R, Stdenis M, Ferris W, Aaron SD, Chan F, Lee C, Ramotar K. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006, 50:55-61. 10.1128/AAC.50.1.55-61.2006, 1346774, 16377667.
18. Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008, 168:805-819. 10.1001/archinte.168.8.805, 18443255.
19. Mandell GL. Uptake, transport, delivery, and intracellular activity of antimicrobial agents. Pharmacotherapy 2005, 25:130S-133S. 10.1592/phco.2005.25.12part2.130S, 16305282.
20. Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 2006, 50:841-851. 10.1128/AAC.50.3.841-851.2006, 1426441, 16495241.
21. Joint Formulary Committee British National Formulary 61 2011, London: British Medical Association and Royal Pharmaceutical Society, Joint Formulary Committee.
22. Schrenzel J, Harbarth S, Schockmel G, Genne D, Bregenzer T, Flueckiger U, Petignat C, Jacobs F, Francioli P, Zimmerli W, Lew DP. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin Infect Dis 2004, 39:1285-1292. 10.1086/424506, 15494904.
23. Ruotsalainen E, Jarvinen A, Koivula I, Kauma H, Rintala E, Lumio J, Kotilainen P, Vaara M, Nikoskelainen J, Valtonen V. Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients. J Intern Med 2006, 259:179-190. 10.1111/j.1365-2796.2005.01598.x, 16420547.
24. Khanlari B, Elzi L, Estermann L, Weisser M, Brett W, Grapow M, Battegay M, Widmer AF, Fluckiger U. A rifampicin-containing antibiotic treatment improves outcome of staphylococcal deep sternal wound infections. J Antimicrob Chemother 2010, 65:1799-1806. 10.1093/jac/dkq182, 20542908.
25. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008, 52:2463-2467. 10.1128/AAC.00300-08, 2443910, 18474578.
26. Lai CC, Tan CK, Lin SH, Liao CH, Huang YT, Hsueh PR. Emergence of rifampicin resistance during rifampicin-containing treatment in elderly patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J Am Geriatr Soc 2010, 58:1001-1003. 10.1111/j.1532-5415.2010.02842.x, 20722839.
27. Ju O, Woolley M, Gordon D. Emergence and spread of rifampicin-resistant, methicillin-resistant Staphylococcus aureus during vancomycin-rifampicin combination therapy in an intensive care unit. Eur J Clin Microbiol Infect Dis 2006, 25:61-62. 10.1007/s10096-005-0063-1, 16331332.
28. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004, 170:445-449. 10.1164/rccm.200404-478OC, 15172892.
29. Van der Auwera P, Klastersky J, Thys JP, Meunier-Carpentier F, Legrand JC. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 1985, 28:467-472. 10.1128/AAC.28.4.467, 180285, 3907494.
30. Van der Auwera P, Meunier-Carpentier F, Klastersky J. Clinical study of combination therapy with oxacillin with rifampicin for staphylococcal infections. Rev Infect Dis 1983, 5:S515-S522.
31. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991, 115:674-680.
32. Jung YJ, Koh Y, Hong SB, Chung JW, Ho Choi S, Kim NJ, Kim MN, Choi IS, Han SY, Kim WD, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010, 38:175-180. 10.1097/CCM.0b013e3181b9ecea, 20050336.
33. Van der Auwera P, Klastersky J. In vitro study of the combination of rifampin with oxacillin against Staphylococcus aureus. Rev Infect Dis 1983, 5(Suppl 3):S509-S514.
34. Thwaites GE. The management of Staphylococcus aureus bacteremia in the United Kingdom and Vietnam: a multi-centre evaluation. PLoS One 2010, 5:e14170. 10.1371/journal.pone.0014170, 3001442, 21179193.
35. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000, 38:1008-1015. 86325, 10698988.
36. Tang YW, Waddington MG, Smith DH, Manahan JM, Kohner PC, Highsmith LM, Li H, Cockerill FR, Thompson RL, Montgomery SO, Persing DH. Comparison of protein A gene sequencing with pulsed-field gel electrophoresis and epidemiologic data for molecular typing of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2000, 38:1347-1351. 86443, 10747105.
37. National Institute for Health and Clinical Excellence Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control 2006, London: Royal College of Physicians, National Institute for Health and Clinical Excellence.